Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqing Oral Liquid is a Traditional Chinese Medicine (TCM) formulation primarily composed of extracts from *Coptis chinensis* (Huanglian), *Scutellaria baicalensis* (Huangqin), and *Rheum palmatum* (Dahuang). It is traditionally used to clear heat and detoxify, addressing symptoms such as sore throat, gingivitis, and mouth ulcers. In the context of the COVID-19 pandemic, it has been investigated for its potential clinical efficacy and safety in treating patients infected with the SARS-CoV-2 Omicron variant, ranging from mild to severe cases. Its mechanism is thought to involve anti-inflammatory and antiviral properties derived from its constituent alkaloids and flavonoids, such as berberine and baicalin, which modulate pro-inflammatory cytokines and potentially interfere with viral replication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqing Oral Liquid.